Sarcoidosis

The Lancet

Volumn 383, Issue 9923, 2014, Pages 1155-1167

  Valeyre, Dominique ^a,b   Prasse, Antje ^c   Nunes, Hilario ^a,b   Uzunhan, Yurdagul ^a,b   Brillet, Pierre Yves ^a,b   Müller Quernheim, Joachim ^c  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; APREMILAST; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CXCR3; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXMETHYLPHENIDATE; DIPEPTIDYL CARBOXYPEPTIDASE; ETANERCEPT; HLA DRB1 ANTIGEN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2; LEFLUNOMIDE; MATRIX METALLOPROTEINASE; METHOTREXATE; MICRORNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PENTOXIFYLLINE; PREDNISONE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; THALIDOMIDE; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; VASOACTIVE INTESTINAL POLYPEPTIDE;

BLAU SYNDROME; CD4 CD8 RATIO; COMMON VARIABLE IMMUNODEFICIENCY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOBRONCHIAL ULTRASONOGRAPHY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FATIGUE; FOLLOW UP; FORCED VITAL CAPACITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GRANULOMA; HEMOPTYSIS; HUMAN; HYPERCALCEMIA; IMMUNE RESPONSE; IMMUNOGLOBULIN DEFICIENCY; LUNG ALVEOLUS MACROPHAGE; LUNG BIOPSY; LUNG FIBROSIS; LUNG LAVAGE; LYMPHADENOPATHY; LYMPHOCYTOSIS; MACROPHAGE; MAINTENANCE THERAPY; MONITORING; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOIDOSIS; T LYMPHOCYTE; WHEEZING;

DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; EXERCISE TEST; GENETIC PREDISPOSITION TO DISEASE; GRANULOMA; HLA-D ANTIGENS; HUMANS; INFLAMMATION; LONG-TERM CARE; PROGNOSIS; SARCOIDOSIS;

EID: 84897042479     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60680-7     Document Type: Conference Paper

References (138)

1. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-55.
2. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361: 1111-18.
3. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573-81.
4. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-99.
5. Hillerdal G, Nou E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 1984; 130: 29-32.
6. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31: 372-79.
7. Varron L, Cottin V, Schott AM, Broussolle C, Seve P. Late-onset sarcoidosis: a comparative study. Medicine (Baltimore) 2012; 91: 137-43.
8. Deubelbeiss U, Gemperli A, Schindler C, Baty F, Brutsche MH. Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur Respir J 2010; 35: 1088-97.
9. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170: 1324-30.
10. Crowley LE, Herbert R, Moline JM, et al. "Sarcoid like" granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med 2011; 54: 175-84.
11. Perlman SE, Friedman S, Galea S, et al. Short-term and medium-term health effects of 9/11. Lancet 2011; 378: 925-34.
12. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164: 2085-91.
13. Sverrild A, Backer V, Kyvik KO, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008; 63: 894-96.
14. Müller-Quernheim J, Schurmann M, Hofmann S, et al. Genetics of sarcoidosis. Clin Chest Med 2008; 29: 391-414.
15. Chen ES, Moller DR. Etiology of sarcoidosis. Clin Chest Med 2008; 29: 365-77.
16. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005; 202: 1715-24.
17. Kalis C, Gumenscheimer M, Freudenberg N, et al. Requirement for TLR9 in the immunomodulatory activity of Propionibacterium acnes. J Immunol 2005; 174: 4295-300.
18. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010; 181: 360-73.
19. Chen ES, White ES. Innate pathways shape sarcoidosis signaling: from bugs to drugs. Am J Respir Crit Care Med 2011; 183: 425-27.
20. Swaisgood CM, Oswald-Richter K, Moeller SD, et al. Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide. Am J Respir Cell Mol Biol 2011; 44: 166-74.
21. Ishige I, Usui Y, Takemura T, Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 1999; 354: 120-23.
22. McCaskill JG, Chason KD, Hua X, et al. Pulmonary immune responses to Propionibacterium acnes in C57BL/6 and BALB/c mice. Am J Respir Cell Mol Biol 2006; 35: 347-56.
23. Zissel G, Prasse A, Müller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med 2010; 31: 390-403.
24. Rastogi R, Du W, Ju D, et al. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit Care Med 2011; 183: 500-10.
25. Wiken M, Grunewald J, Eklund A, Wahlstrom J. Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. J Clin Immunol. 2009; 29: 78-89.
26. Pignatti P, Brunetti G, Moretto D, et al. Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am J Respir Crit Care Med 2006; 173: 310-17.
27. Facco M, Cabrelle A, Teramo A, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011; 66: 144-50.
28. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203: 359-70.
29. Prasse A, Zissel G, Lutzen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010; 182: 540-48.
30. Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 154: 713-19.
31. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802.
32. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156: 1601-05.
33. Grunewald J, Idali F, Kockum I, et al. Major histocompatibility complex class II transactivator gene polymorphism: associations with Lofgren's syndrome. Tissue Antigens 2010; 76: 96-101.
34. Sato H, Woodhead FA, Ahmad T, et al. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Mol Genet 2010; 19: 4100-11.
35. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73: 720-35.
36. Veltkamp M, van Moorsel CH, Rijkers GT, Ruven HJ, Grutters JC. Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis. Tissue Antigens 2012; 79: 25-32.
37. Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37: 357-64.
38. Hofmann S, Franke A, Fischer A, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008; 40: 1103-06.
39. Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol 2006; 176: 7354-60.
40. Lockstone HE, Sanderson S, Kulakova N, et al. Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med 2010; 181: 1367-75.
41. Crouser ED, Culver DA, Knox KS, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009; 179: 929-38.
42. Navani N, Lawrence DR, Kolvekar S, et al. Endobronchial ultrasound-guided transbronchial needle aspiration prevents mediastinoscopies in the diagnosis of isolated mediastinal lymphadenopathy: a prospective trial. Am J Respir Crit Care Med 2012; 186: 255-60.
43. Plit ML, Havryk AP, Hodgson A, et al. Rapid cytological analysis of endobronchial ultrasound-guided aspirates in sarcoidosis. Eur Respir J 2012; published online Nov 22. DOI:10.1183/09031936.00128312.
44. Mostard RL, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F8 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011; 105: 1917-24.
45. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 8F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012; 53: 1543-49.
46. Mostard RL, Van Kuijk SM, Verschakelen JA, et al. A predictive tool for an effective use of 8F-FDG PET in assessing activity of sarcoidosis. BMC Pulm Med 2012; 12: 57.
47. Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 8F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 123-29.
48. Youssef G, Leung E, Mylonas I, et al. The use of 8F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53: 241-48.
49. Soussan M, Brillet P Y, Nunes H, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013; 20: 120-27.
50. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40: 255-63.
51. Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis. Respir Med 2011; 105: 95-100.
52. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138: 1078-85.
53. Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013; 68: 57-65.
54. Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest 2003; 123: 406-12.
55. Criado E, Sanchez M, Ramirez J, et al. Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiographics 2010; 30: 1567-86.
56. Mana J, Marcoval J. Skin manifestations of sarcoidosis. Presse Med 2012; 41: e355-74.
57. Judson MA. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28: 83-101.
58. Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first international workshop on ocular sarcoidosis (IWOS). Ocul Immunol Inflamm 2009; 17: 160-69.
59. Bodaghi B, Touitou V, Fardeau C, Chapelon C, LeHoang P. Ocular sarcoidosis. Presse Med 2012; 41: e349-54.
60. Cremers J, Drent M, Driessen A, et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol 2012; 24: 17-24.
61. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012; 141: 154-62.
62. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120: 1969-77.
63. Nozaki K, Scott TF, Sohn M, Judson MA. Isolated neurosarcoidosis: case series in 2 sarcoidosis centers. Neurologist 2012; 18: 373-77.
64. Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3: 397-407.
65. Cohen-Aubart F, Galanaud D, Grabli D, et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 2010; 89: 133-40.
66. Mahevas M, Lescure FX, Boffa JJ, et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore) 2009; 88: 98-106.
67. Sweiss NJ, Patterson K, Sawaqed R, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med 2010; 31: 463-73.
68. Nunes H, Uzunhan Y, Gille T, Lamberto C, Valeyre D, Brillet PY. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. Eur Respir J 2012; 40: 750-65.
69. Costabel U, Bonella F, Ohshimo S, Guzman J. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. Semin Respir Crit Care Med 2010; 31: 404-08.
70. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet 2008; 372: 489-502.
71. Müller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006; 27: 1190-95.
72. Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009; 136: 526-35.
73. Nunes H, Brillet PY, Valeyre D, Brauner MW, Wells AU. Imaging in sarcoidosis. Semin Respir Crit Care Med 2007; 28:102-20.
74. Erdal BS, Crouser ED, Yildiz V, et al. Quantitative computerized two-point correlation analysis of lung CT scans correlates with pulmonary function in pulmonary sarcoidosis. Chest 2012; 142: 1589-97.
75. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132: 207-13.
76. Marcellis RG, Lenssen AF, de Vries GJ, et al. Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients? Lung 2013; 191: 43-52.
77. Wallaert B, Talleu C, Wemeau-Stervinou L, Duhamel A, Robin S, Aguilaniu B. Reduction of maximal oxygen uptake in sarcoidosis: relationship with disease severity. Respiration 2011; 826: 501-08.
78. Lopes AJ, Menezes SL, Dias CM, Oliveira JF, Mainenti MR, Guimaraes FS. Cardiopulmonary exercise testing variables as predictors of long-term outcome in thoracic sarcoidosis. Braz J Med Biol Res 2012; 45: 256-63.
79. Kollert F, Geck B, Suchy R, et al. The impact of gas exchange measurement during exercise in pulmonary sarcoidosis. Respir Med 2011; 105: 122-29.
80. Nunes H, Uzunhan Y, Freynet O, et al. Pulmonary hypertension complicating sarcoidosis. Presse Med 2012; 41: e303-16.
81. 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 87-94.
82. Schuller JL, Olson MD, Zipse MM, et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol 2011; 22: 1243-48.
83. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management. QJM 1999; 92: 103-17.
84. Hoitsma E, Marziniak M, Faber CG, et al. Small fibre neuropathy in sarcoidosis. Lancet 2002; 359: 2085-86.
85. De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS). Br J Health Psychol 2004; 9: 279-91.
86. Elfferich MD, Nelemans PJ, Ponds R W, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010; 80: 212-19.
87. De Vries J, Lower EE, Drent M. Quality of life in sarcoidosis: assessment and management. Semin Respir Crit Care Med 2010; 31: 485-93.
88. Biller H, Zissel G, Ruprecht B, Nauck M, Busse Grawitz A, Müller-Quernheim J. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J 2006; 28: 1085-90.
89. Bargagli E, Bennett D, Maggiorelli C, et al. Human chitotriosidase: a sensitive biomarker of sarcoidosis. J Clin Immunol 2013; 33: 264-70.
90. Bargagli E, Magi B, Olivieri C, Bianchi N, Landi C, Rottoli P. Analysis of serum amyloid A in sarcoidosis patients. Respir Med 2011; 105: 775-80.
91. Mahevas M, Chiche L, Uzunhan Y, et al. Association of sarcoidosis and immune thrombocytopenia: presentation and outcome in a series of 20 patients. Medicine (Baltimore) 2011; 90: 269-78.
92. Handa T, Nagai S, Ueda S, et al. Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 27-35.
93. Baba Y, Kubo T, Kitaoka H, et al. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis. Int Heart J 2012; 53: 287-92.
94. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q JM 1983; 52: 525-33.
95. Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Müller-Quernheim J. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 2008; 177: 330-36.
96. WasfiYS, Rose CS, Murphy JR, et al. A new tool to assess sarcoidosis severity. Chest 2006; 129: 1234-45.
97. Ziegenhagen MW, Rothe ME, Schlaak M, Müller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003; 21: 407-13.
98. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med 2010; 31: 409-18.
99. Zappala CJ, Desai SR, Copley SJ, et al. Optimal scoring of serial change on chest radiography in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 130-38.
100. Judson MA, Gilbert GE, Rodgers JK, Greer CF, Schabel SI. The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis. Respirology 2008; 13: 97-102.
101. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 52-58.
102. King TE Jr. Restrictive lung disease in pregnancy. Clin Chest Med 1992; 13: 607-22.
103. Nardi A, Brillet P Y, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2012; 38: 1368-73.
104. Gribbin J, Hubbard RB, Le JI, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-85.
105. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011; 183: 1524-30.
106. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922-28.
107. Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011; 140: 1261-66.
108. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104: 717-23.
109. Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-22.
110. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-50.
111. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148: 147-48.
112. Park MK, Fontana JR, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 121-31.
113. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-69.
114. Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 51-57.
115. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 76-89.
116. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160: 192-97.
117. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 (suppl): v1-58.
118. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: 238-47.
119. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005 2: CD001114.
120. Paramothayan S, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2006; 3: CD003536.
121. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128: 1062-67.
122. Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-08.
123. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133: 1189-95.
124. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115: 1158-65.
125. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121: 24-31.
126. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66.
127. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-48.
128. Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 49-56.
129. Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103: 268-73.
130. Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135: 468-76.
131. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-85.
132. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 713-20.
133. Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012; 6: 1613-18.
134. Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148: 262-64.
135. Corte TJ, Wells AU, Nicholson AG, Hansell DM, Wort SJ. Pulmonary hypertension in sarcoidosis: a review. Respirology 2011; 16: 69-77.
136. Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med 2010; 31: 474-84.
137. Shah L. Lung transplantation in sarcoidosis. Semin Respir Crit Care Med 2007; 28: 134-40.
138. Collins J, Hartman MJ, Warner TF, et al. Frequency and CT findings of recurrent disease after lung transplantation. Radiology 2001; 219: 503-09.